2. Academic Validation
  3. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors

Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors

  • J Med Chem. 2022 Dec 22;65(24):16902-16917. doi: 10.1021/acs.jmedchem.2c01716.
Shenghua Gao 1 2,  Letian Song 1,  Tobias Claff 3,  Molly Woodson 4 5,  Katharina Sylvester 3,  Lanlan Jing 1,  Renato H Weiße 6,  Yusen Cheng 1,  Norbert Sträter 6,  Laura Schäkel 3,  Michael Gütschow 3,  Bing Ye 1,  Mianling Yang 1,  Tao Zhang 7,  Dongwei Kang 1,  Karoly Toth 4 5,  John Tavis 4 5,  Ann E Tollefson 4 5,  Christa E Müller 3,  Peng Zhan 1,  Xinyong Liu 1
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Ji'nan250012, China.
  • 2 Shenzhen Research Institute of Shandong University, A301 Virtual University Park in South District, Shenzhen518057, Guangdong, China.
  • 3 PharmaCenter Bonn & Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, Bonn53113, Germany.
  • 4 Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri63104, United States.
  • 5 Saint Louis University Institute for Drug and Biotherapeutic Innovation, St. Louis, Missouri63104, United States.
  • 6 Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, Leipzig04103, Germany.
  • 7 Shandong Qidu Pharmaceutical Research Institute, Yinfeng Biological City, Chunlan Road 1177, High Tech District, Ji'nan250101, China.
PMID: 36475694 DOI: 10.1021/acs.jmedchem.2c01716
Abstract

The spread of SARS-CoV-2 keeps threatening human life and health, and small-molecule antivirals are in demand. The main protease (Mpro) is an effective and highly conserved target for anti-SARS-CoV-2 drug design. Herein, we report the discovery of potent covalent non-peptide-derived Mpro inhibitors. A series of covalent compounds with a piperazine scaffold containing different warheads were designed and synthesized. Among them, GD-9 was identified as the most potent compound with a significant enzymatic inhibition of Mpro (IC50 = 0.18 μM) and good Antiviral potency against SARS-CoV-2 (EC50 = 2.64 μM), similar to that of remdesivir (EC50 = 2.27 μM). Additionally, GD-9 presented favorable target selectivity for SARS-CoV-2 Mpro versus human cysteine proteases. The X-ray co-crystal structure confirmed our original design concept showing that GD-9 covalently binds to the active site of Mpro. Our nonpeptidic covalent inhibitors provide a basis for the future development of more efficient COVID-19 therapeutics.

Figures
Products